86 related articles for article (PubMed ID: 23404140)
1. Bioinformatic analysis of chemokine (C-C motif) ligand 21 and SPARC-like protein 1 revealing their associations with drug resistance in ovarian cancer.
Yin F; Liu X; Li D; Wang Q; Zhang W; Li L
Int J Oncol; 2013 Apr; 42(4):1305-16. PubMed ID: 23404140
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of NEK2 is associated with drug resistance in ovarian cancer.
Liu X; Gao Y; Lu Y; Zhang J; Li L; Yin F
Oncol Rep; 2014 Feb; 31(2):745-54. PubMed ID: 24337664
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of NEK11 is associated with drug resistance in ovarian cancer.
Liu X; Gao Y; Lu Y; Zhang J; Li L; Yin F
Int J Oncol; 2014 Sep; 45(3):1266-74. PubMed ID: 24969318
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of HNF1 homeobox B is associated with drug resistance in ovarian cancer.
Li J; Zhang Y; Gao Y; Cui Y; Liu H; Li M; Tian Y
Oncol Rep; 2014 Sep; 32(3):979-88. PubMed ID: 24968817
[TBL] [Abstract][Full Text] [Related]
5. Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer.
Esposito I; Kayed H; Keleg S; Giese T; Sage EH; Schirmacher P; Friess H; Kleeff J
Neoplasia; 2007 Jan; 9(1):8-17. PubMed ID: 17325739
[TBL] [Abstract][Full Text] [Related]
6. Genomic organization and chromosomal mapping of SPARC-like 1, a gene down regulated in cancers.
Isler SG; Schenk S; Bendik I; Schraml P; Novotna H; Moch H; Sauter G; Ludwig CU
Int J Oncol; 2001 Mar; 18(3):521-6. PubMed ID: 11179481
[TBL] [Abstract][Full Text] [Related]
7. Secreted protein acidic and rich in cysteines-like 1 suppresses aggressiveness and predicts better survival in colorectal cancers.
Hu H; Zhang H; Ge W; Liu X; Loera S; Chu P; Chen H; Peng J; Zhou L; Yu S; Yuan Y; Zhang S; Lai L; Yen Y; Zheng S
Clin Cancer Res; 2012 Oct; 18(19):5438-48. PubMed ID: 22891198
[TBL] [Abstract][Full Text] [Related]
8. Down-regulated SPARCL1 is associated with clinical significance in human gastric cancer.
Li P; Qian J; Yu G; Chen Y; Liu K; Li J; Wang J
J Surg Oncol; 2012 Jan; 105(1):31-7. PubMed ID: 22161898
[TBL] [Abstract][Full Text] [Related]
9. Role of microRNAs in drug-resistant ovarian cancer cells.
Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C
Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650
[TBL] [Abstract][Full Text] [Related]
10. Tumor suppressor genes associated with drug resistance in ovarian cancer (review).
Yin F; Liu X; Li D; Wang Q; Zhang W; Li L
Oncol Rep; 2013 Jul; 30(1):3-10. PubMed ID: 23660957
[TBL] [Abstract][Full Text] [Related]
11. SPARCL1 a novel player in cancer biology.
Gagliardi F; Narayanan A; Mortini P
Crit Rev Oncol Hematol; 2017 Jan; 109():63-68. PubMed ID: 28010899
[TBL] [Abstract][Full Text] [Related]
12. Integrated genomics of chemotherapy resistant ovarian cancer: a role for extracellular matrix, TGFbeta and regulating microRNAs.
Helleman J; Jansen MP; Burger C; van der Burg ME; Berns EM
Int J Biochem Cell Biol; 2010 Jan; 42(1):25-30. PubMed ID: 19854294
[TBL] [Abstract][Full Text] [Related]
13. SPARC and Hevin expression correlate with tumour angiogenesis in hepatocellular carcinoma.
Lau CP; Poon RT; Cheung ST; Yu WC; Fan ST
J Pathol; 2006 Dec; 210(4):459-68. PubMed ID: 17029219
[TBL] [Abstract][Full Text] [Related]
14. Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture.
Helleman J; Smid M; Jansen MP; van der Burg ME; Berns EM
Gynecol Oncol; 2010 May; 117(2):170-6. PubMed ID: 20132968
[TBL] [Abstract][Full Text] [Related]
15. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance.
Yang L; Li N; Wang H; Jia X; Wang X; Luo J
Oncol Rep; 2012 Aug; 28(2):592-600. PubMed ID: 22614869
[TBL] [Abstract][Full Text] [Related]
16. Characterization of MAST9/Hevin, a SPARC-like protein, that is down-regulated in non-small cell lung cancer.
Bendik I; Schraml P; Ludwig CU
Cancer Res; 1998 Feb; 58(4):626-9. PubMed ID: 9485012
[TBL] [Abstract][Full Text] [Related]
17. MicroRNAs in ovarian cancer biology and therapy resistance.
van Jaarsveld MT; Helleman J; Berns EM; Wiemer EA
Int J Biochem Cell Biol; 2010 Aug; 42(8):1282-90. PubMed ID: 20083225
[TBL] [Abstract][Full Text] [Related]
18. Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer.
Shridhar V; Bible KC; Staub J; Avula R; Lee YK; Kalli K; Huang H; Hartmann LC; Kaufmann SH; Smith DI
Cancer Res; 2001 May; 61(10):4258-65. PubMed ID: 11358853
[TBL] [Abstract][Full Text] [Related]
19. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.
Li Z; Hu S; Wang J; Cai J; Xiao L; Yu L; Wang Z
Gynecol Oncol; 2010 Oct; 119(1):125-30. PubMed ID: 20624637
[TBL] [Abstract][Full Text] [Related]
20. Candidate gene analysis of SPARCL1 gene in patients with multiple sclerosis.
Scalabrini D; Fenoglio C; Scarpini E; De Riz M; Comi C; Venturelli E; Cortini F; Piola M; Villa C; Naldi P; Monaco F; Bresolin N; Galimberti D
Neurosci Lett; 2007 Oct; 425(3):173-6. PubMed ID: 17825989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
